Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » PPO Stratose to Cover Paradigm's PCDx Cancer Test

PPO Stratose to Cover Paradigm's PCDx Cancer Test

Jul 15, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm today said that it and preferred provider organization Stratose have entered into a contract to cover the PCDx test. 

Stratose, based in Atlanta, has more than 850,000 direct and affiliate contracts with providers nationwide. Stratose's members will now have access to the PCDx next-generation sequencing-based test, which identifies the underlying genomic and proteomic mutations in a patient's tumor DNA, RNA, and proteins. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

This One Might Not Be Due to Humans

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Not the Wings

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

More Vaccines on Order

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

Science Studies Include Ion Channel Mutation Prediction Model, Variant Linked to Disrupted Sleep

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
26
Featured Webinar

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. 

Sep
01
Featured Webinar

Application of Whole-Exome Sequencing in Neurodevelopmental Disorders Research

Sponsored by
Roche

This webinar will address the utility of exome sequencing for neurodevelopmental disorders research and will provide details of a comparison study of two exome probe kits in this field of study.

What's Popular?

In Sequencing

  1. NanoString Launches NGS Readout for Spatial Transcriptomics, Partners With Illumina on Informatics

    Premium

  2. Mission Bio Raises $70M in Series C Funding Round

  3. Triple-Negative Breast Cancer Treatment Hints Drawn From Single-Cell Study

  4. Mission Bio Seeks to Increase Drug Trial Collaborations, Improve Gene and Cell Therapy Efficacy

    Premium

  5. Pacific Biosciences Prices $86.9M Public Stock Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.